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CLINICAL RESEARCH STUDIES
Dacron prostheses have been used as arterial
bypass grafts since 1957,1 and polytetrafluoroethylene
(PTFE) arterial bypass grafts were clinically introduced
in 1975.2 These two types of bypass grafts are current-
ly being used for femorofemoral, axillofemoral, and
axillobifemoral revascularizations. Bypass graft choice
is the surgeon’s preference because until recently no
prospective comparative evaluation of these alternative
conduits had been performed in the United States. 
The physical and chemical characteristics of
Dacron and PTFE are quite different. Dacron is
manufactured as either woven or knitted polyethyl-
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ene with various properties of porosity and velour.
PTFE is an expanded matrix of PTFE, which is 80%
space. The “non-wetability” of the PTFE surface
prevents bleeding through the bypass graft and 
may retard early thrombosis. The handling charac-
teristics of each conduit are different. Dacron is
quite flexible, with PTFE being more rigid. The final
pseudointima that forms in each bypass graft may be
similar. Anastomotic hyperplastic responses may be
different for each bypass graft.
In 1983, Veterans Affairs Cooperative Study
#141 was initiated to evaluate the efficacy of exter-
nally supported knitted Dacron and PTFE bypass
grafts in lower limb revascularization. The observa-
tions of this study are the basis of this report.
METHODS 
At 20 Department of Veterans Affairs Medical
Centers (DVAMCs), patients scheduled for femoro-
femoral, axillofemoral, and axillobifemoral bypass
grafts were solicited for participation. Arterial ischemia
was categorized as claudication, rest pain, or tissue
necrosis. Risk factors that were prospectively recorded
included the presence of diabetes, prior vascular recon-
struction, heart disease, cerebrovascular events, and
smoking. Physical findings that were recorded were
peripheral pulses and Doppler-scanning pressure mea-
surements at the high thigh, low thigh, calf, and ankle
levels. The leg pressures were compared with the high-
est brachial pressure to give the leg/brachial index at
these levels (high thigh–brachial index [HTBI], low
thigh brachial index, calf brachial index, ankle-brachial
index [ABI]). Patients with calcified vessels or an ABI
of more than 0.9 in the recipient limb were excluded
from study entry. Patients were also excluded if they
had a prior prosthetic femorofemoral or axillofemoral
reconstruction. Other exclusionary factors were emer-
gency surgery, short (<1 year) life expectancy, oral
anticoagulation, aortic aneurysmal disease, serum crea-
tinine value of more than 2.0 mg/dL (180 m mol/L),
polycythemia (red blood cell count, >7.5 · 106/mm3),
and/or platelet count more than 106/mm2. Informed
consent was obtained from all participants. Patients
were considered to be a candidate for femorofemoral
revascularization if by physical examination there was a
good femoral pulse on the donor side and if the
angiogram did not reveal a significant (>50% diameter
reduction) in the donor iliac system.
Random assignment to either a PTFE or a Dacron
bypass graft was determined in the operating room.
The PTFE bypass grafts (W.L. Gore, Inc, Flagstaff,
Ariz) were “light weight” with an external support
coil. The Dacron bypass grafts (Bard Cardiosurgery
Division, Inc, Billerica, Mass) were knitted grafts with
an external coil. Graft diameter was either 6 or 8 mm
as chosen by the surgeon. All Dacron bypass grafts
were preclotted with nonheparinized blood by the
Sauvage technique.3 All patients were instructed to
take aspirin (650 mg/day) after the operation for the
duration of the study, and all patients had received
325 mg of aspirin the evening before the operation.
At each facility, there was a participating investi-
gator and a study coordinator who were dedicated
to the enrollment and serial evaluation of study
patients. After the operation, the patients were eval-
uated periodically for the current status of symp-
toms, pulses, and Doppler-scanning pressure deter-
minations. These evaluations were performed on
postoperative days 1, 5, and 10 and at the time of
hospital discharge. After discharge, patients were
seen every 3 months during the first year and every
6 months thereafter. Patients were terminated from
the study if they died, had an above-knee or below-
knee amputation with a patent graft, or could not be
located for at least 12 months. All data were for-
warded on study forms to a central statistical center
for computer entry, storage, and analysis.
All patients were followed at all medical centers
until June 1989 when VA funding for this specific
study was terminated as planned. However, other VA-
funded vascular cooperative studies at 12 DVAMCs
allowed the continued observation of 119 of the 144
currently patent bypass grafts until June 1991. For the
patency analysis the remaining 25 bypass grafts were
considered patent but scored as lost to follow-up as of
June 1989. 
Patency evaluation. Bypass grafts were consid-
ered patent if the postoperative ABI remained 0.15 or
more above the preoperative values.4 However, avail-
able angiograms, operative reports, and Doppler-ABI
analysis (transient low values were discarded if subse-
quent ABI were elevated and suggested patency) were
used to score the final patency status. Patency rates
reported in this study are cumulative “assisted prima-
ry” patency rates,5 because remedial surgery was
allowed for graft stenosis but not for graft thrombo-
sis. An axillobifemoral graft was considered patent as
long as the leg ipsilateral to the axillofemoral bypass
graft maintained an ABI of more than 0.15 above the
preoperative value. (No attempt was made to score
the patency of the femorofemoral bypass graft in
patients with an axillofemoral bypass graft.) Removal
of a patent graft because of an infection was scored as
a bypass graft patency failure at that time. 
Statistical analysis. The data analysis is based
on “intent to treat” (ie, patients were placed into the
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bypass graft group to which they were randomized,
regardless of bypass graft material actually received).
During the course of this study, two centers with a
total of 5 patients were replaced because of low
recruitment. These five patients remain in the paten-
cy data analysis but were censored as “lost to follow-
up” at the date that they were last seen before their
center was replaced. A third Center was replaced
when the validity of the postoperative patency eval-
uations became questionable. The data from the lat-
ter Center have been deleted from analysis on the
recommendation of the Data Monitoring Board, an
independent monitoring body.
Proportions and categoric-type data were com-
pared with a chi-squared test. Continuous data were
compared with Student t test. Kaplan-Meier life table
analyses were performed on the time-to-graft failure
data with SAS (SAS Institute Inc, Cary, NC) and
BMDP (BMDP Statistical Software Inc, Los Angeles,
Calif). All tests were two-sided, and statistical signifi-
cance was indicated by a P value of less than .05.
RESULTS
Enrollment. Between June 1983 and June 1988,
5854 patients who were candidates for vascular opera-
tions to improve lower leg arterial perfusion were
screened for inclusion into VA Cooperative Study
#141 at 20 participating DVAMCs. After the initial
screening, 2195 patients (37% of the screened
patients) were still eligible. Two thousand thirty-nine
patients signed a consent form, and 1892 patients par-
ticipated in the study. Prior reports have presented the
outcome of patients with infrainguinal outflow bypass
grafts.6 This article reports on the 436 patients who
received an inflow-level bypass graft and were ran-
domized to receive either an externally supported
PTFE or Dacron graft. After randomization, 17 pa-
tients were excluded; the reasons included the
patient’s vessels being calcified at baseline (2 patients),
patients who had a previous femorofemoral or
axillofemoral bypass graft (5 patients), abandoned
planned surgery (4 patients), prior participation in
Cooperative Study #141 (1 patient), an immediate
above-knee amputation on the study limb (1 patient),
early postoperative abusive behavior (1 patient), emer-
gency surgery (1 patient), paraplegia (1 patient), and
operative thrombectomy of recipient iliac system (1
patient). Therefore 340 patients with femorofemoral
and 79 patients with either axillofemoral (16 patients)
or axillofemorofemoral (63 patients) bypass grafts con-
stitute the study population. Two hundred eight
patients were randomized to receive PTFE graft con-
duits, and 211 patients were randomized to receive
Dacron bypass graft conduits. No patient had a simul-
taneous infrainguinal bypass graft. 
The baseline characteristics of the patients in this
study are presented in Table I. The patients in the
two prosthetic bypass graft groups are homogeneous
with respect to the characteristics listed. All patients
were men; almost all patients have used tobacco;
40% of the patients are self-declared heavy drinkers;
50% of the patients are hypertensive; approximate-
ly 33% of the patients have had a previous myocar-
dial infarction; approximately 17% of the patients
have experienced a prior stroke, and approximately
10% of the patients have undergone coronary artery
bypass grafting. The average patient is 62.5 years old.
Baseline ischemic symptoms are also presented in
Table I. There were no differences between the two
bypass graft material groups; 28% of the patients had
only claudication as the indication for the bypass
surgery, and 72% of the patients had a limb salvage
operation (45% for rest pain and 27% for tissue
necrosis). The mean preoperative baseline ABI was
0.33 while the HTBI was 0.60. Almost all of the
patients with axillofemoral bypass grafts and approx-
imately 55% of the patients with femorofemoral
bypass grafts had a severely stenotic or occluded
superficial femoral artery, and approximately 65% of
the patients with axillobifemoral bypass grafts had at
least one extremity with a severely stenotic or
occluded superficial femoral artery. These propor-
tions did not differ by graft material.
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Table I. Baseline characteristics by bypass graft
material
Characteristic PTFE Dacron
Mean age (y) 62.7 62.4
Diabetes mellitus (%) 23 18
Prior lower limb major 8 11
amputation (%)
Prior vascular bypass grafting 44 40
operation (%)
Prior myocardial infarction (%) 37 31
Prior coronary bypass grafting (%) 11 9
Hypertension (%) 50 47
Prior strokes (%) 21 18
Used tobacco (%) 99 98
Heavy drinker (%) 48 44
Contraindication to aspirin (%) 13 17
Worst symptom
Claudication (%) 27 28
Rest pain (%) 45 45
Ischemic necrosis (%) 28 27
Baseline ABI 0.32 ± 0.02* 0.36 ± 0.02*
Baseline HTBI 0.59 ± 0.03* 0.60 ± 0.02*
*SEM.
Ten patients did not receive the randomized
bypass graft: seven patients received a PTFE femoro-
femoral bypass graft rather than a Dacron bypass
graft, mainly because of inadvertent heparinization
(five cases); two patients received a Dacron bypass
graft rather than a PTFE femorofemoral bypass graft,
and one patient received a PTFE axillofemoral bypass
graft rather than a Dacron bypass graft. This
“crossover” of bypass graft conduits was not consid-
ered in the patency analysis. Of the eight crossover
PTFE bypass grafts, three of the grafts failed; neither
Dacron bypass graft failed. Patency outcome by actu-
al treatment was the same as by intention to treat.
Study patients were administered perioperative
antibiotics, heparin, and dextran. During the initial
operation, 23% of the patients received a femoral
endarterectomy, and approximately one third of the
patients required a femoral profundoplasty. These
events occurred with similar frequency in the two
material groups. 
The 30-day operative mortality rate was similar in
each group (1.5% in the Dacron group; 2.0% in the
PTFE group). There were a similar number of infect-
ed bypass grafts (3.5%; 7 Dacron grafts and 5 PTFE
grafts). These bypass grafts were scored as failures in
the patency determinations. Bypass graft seroma that
required operative intervention was rare (2 in PTFE
group). Early operations (< 30 days) were performed
in 3 patients with PTFE bypass grafts for kinking,
bleeding, and anastomotic pseudoaneurysm.
Antiplatelet therapy. Aspirin compliance was
recorded on each postoperative visit by the study
coordinator; this was monitored by pill counting and
by patient self-reporting. During the course of the
study, 60% to 75% of dispensed aspirin bottles were
returned. If compliance were defined as having at least
50% of the expected number of pills “consumed,”
then about 90% of the patients who returned their
aspirin bottles were compliant. This high rate of com-
pliance was echoed by the patient self-reporting of
regularly taking this medication. There was no differ-
ence in compliance between patients with PTFE or
Dacron bypass grafts. 
Patency. Tables II and III present the cumulative
patency rates for the femorofemoral and axillofemoro-
femoral bypass grafts. There was no statistical differ-
ence between graft materials. The time to failure data
for all bypass grafts were analyzed (the survival curves
are presented in Fig 1); the curves are similar, suggest-
ing that Dacron and PTFE bypass grafts have the same
risk of failure (Savage statistical analysis of patency
curves). To evaluate the possibility of a true difference
in the patency that exists between graft materials, we
determined the power with an a = 0.05 (two-sided)
for a group of 210 patients at 2 years, with a median
patency of 60%. For a possible difference of 15% in
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Table II. Cumulative femorofemoral bypass graft
patency
Lost to Cumulative
Interval At risk Failed follow-up patency at end SEM
(mo) (n) (n) or death (n) of interval (%) (%)
Dacron
0-6 175 26 25 84.0 2.9
6-12 124 6 11 80.0 3.2
12-18 107 7 8 74.3 3.6
18-24 92 8 8 67.6 4.0
24-30 76 3 3 64.8 4.1
30-36 70 4 3 61.0 4.3
36-42 63 3 8 58.0 4.4
42-48 52 5 5 52.1 4.7
48-54 42 2 5 49.4 4.8
54-60 35 0 6 49.4 4.8
PTFE
0-6 165 23 29 84.7 3.0
6-12 113 9 16 77.2 3.6
12-18 88 3 7 74.5 3.8
18-24 78 5 7 69.5 4.2
24-30 66 5 8 63.9 4.5
30-36 53 2 4 61.2 4.7
36-42 47 2 14 58.3 4.9
42-48 31 3 4 52.3 5.5
48-54 24 1 7 49.7 5.8
54-60 16 1 2 46.4 6.3
Table III. Cumulative axillofemorofemoral bypass
graft patency
Lost to Cumulative
Interval At risk Failed follow-up patency at end SEM
(mo) (n) (n) or death (n) of interval (%) (%)
Dacron
0-6 30 9 5 66.5 9.2
6-12 16 1 1 62.3 9.5
12-18 14 1 2 57.5 9.9
18-24 11 0 0 57.5 9.9
24-30 11 0 1 57.5 9.9
36-38 10 0 1 57.5 9.9
36-42 9 1 0 51.1 10.7
42-48 8 0 2 51.1 10.7
48-54 6 0 2 51.1 10.7
54-60 4 0 1 51.1 10.7
PTFE
0-6 33 10 7 65.4 8.9
6-12 16 1 3 60.9 9.4
12-18 12 2 1 50.3 10.3
18-24 9 1 2 44.0 10.8
24-30 6 0 0 44.0 10.8
30-36 6 0 1 44.0 10.8
36-42 5 1 1 34.2 12.0
42-48 3 0 1 34.2 12.0
48-54 2 0 0 34.2 12.0
54-60 2 0 1 34.2 12.0
patency, the power is 0.87 or a 13% chance of detect-
ing a difference. For a possible 10% difference in
patency, the power is 0.56 or a 44% chance of detect-
ing a difference. Five patients had failure of their femo-
rofemoral bypass graft within the early postoperative
period (<24 hours). These 5 bypass grafts (2 PTFE
and 3 Dacron grafts) were salvaged by a thrombecto-
my. No acute occlusion occurred in the axillofemoro-
femoral group. The early failure rate, within 30 days,
for axillofemoral or axillofemorofemoral bypass grafts
was 0% for PTFE bypass grafts and 9% for Dacron
bypass grafts. Although there was a small number (16
grafts) of unilateral axillofemoral bypass grafts inserted,
only two Dacron bypass grafts failed. 
A detailed analysis of the failure of femoro-
femoral bypass grafts, as related to possible inade-
quate flow within the donor iliac artery in this study
group, has previously been published.7 Nineteen
percent of patients had a clinical or hemodynamic
steal. Subsequently, in those patients with a steal,
bypass graft thrombosis occurred in 7 of 31 patients
with a Dacron bypass graft and in 16 of 33 patients
with a PTFE bypass graft. 
DISCUSSION
The results of this clinical study suggest that, in
elderly male patients who require extra-anatomic
inflow revascularization, externally supported Dacron
and PTFE bypass grafts (which have quite different
physical and chemical characteristics) but have similar
long-term patency.
There are only a few comparative studies that have
evaluated Dacron and PTFE conduits, only three of
which were prospective randomized studies. Polter-
auer et al8 randomized 165 patients to either Dacron
or PTFE aortic bifurcation bypass grafts. The 95% 3-
year patency rates were identical for PTFE and Dacron
conduits. Lord et al9 randomized 80 patients to PTFE
or Dacron aortic bifurcation bypass grafts. During a
short period of follow-up, only one bypass graft has
occluded, a Dacron bypass graft. Cintora et al10 com-
pared 142 Bard knitted bifurcated Dacron bypass
grafts and 170 Gore PTFE bifurcated bypass grafts in
patients who underwent aortic reconstruction for
aneurysmal or occlusive disease. There was no signifi-
cant difference in patency between these 2 bypass graft
materials; there was a minor trend in favor of PTFE
bypass grafts, but these bypass grafts may have had bet-
ter outflow than the Dacron bypass graft. Miller and
Berce11 recently reported their experience with 401
femorofemoral bypass grafts, initially in 131 patients
with Dacron bypass grafts and more recently in 270
patients with PTFE bypass grafts. Cumulative primary
patency was 86% at 2 years, 74% at 4 years, and 65% 
at 6 years, with no significant differences between 
a PTFE and Dacron bypass grafts. Broome et al12
reported their experience with 31 Dacron (velour) and
30 PTFE axillofemoral bypass grafts. By life table
analysis, patency rates at 4 years were not significantly
different. For many years, Sauvage3 prospectively eval-
uated externally supported Dacron bypass grafts with
regard to host interaction and patency. Recent reports
on axillofemoral bypass grafts suggest that a Dacron
bypass grafts13 may be equally as efficacious as PTFE
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Fig 1. Comparative assisted primary patency for all randomized PTFE and Dacron
axillofemoral and femorofemoral bypass grafts.
bypass grafts.14,15 In a recent randomized study of
femoropopliteal bypass grafts, Abbott et al16 reported
similar patency results for Dacron and PTFE.
There are no other prospective randomized stud-
ies that compare the patency performance of Dacron
and PTFE bypass grafts in patients with axillofemoral
or femorofemoral bypass grafts. Although the patients
presented in this study had the bypass grafting per-
formed in the late 1980s, these bypass grafts were all
externally supported and represented the most recent
changes in graft design. These same bypass grafts are
currently still the bypass grafts of choice; therefore
these results are valid for providing guidance to the
vascular surgeon in the choice of a bypass graft in the
late 1990s. Technology has not made this an outdat-
ed study.
Patency evaluation. The patency criteria for
this study, which were defined in 1983 at the initia-
tion of this study, are remarkably similar to the stan-
dards suggested in 1986 and updated in 1997 by the
Ad Hoc Committee on Reporting Standards of the
Society of Vascular Surgery/International Society
for Cardiovascular Surgery.5 We chose an increase of
0.15 rather than 0.10 above the preoperative seg-
mental limb pressure index because this most likely
exceeded the standard error of measurement by two
standard deviations.17 Others4 have also proposed
this level as more appropriate than the 0.10 pro-
posed by the Standards Committee.5 The success of
thrombectomy in failed grafts (ie, “secondary paten-
cy”) was not determined because only five patients
underwent successful early thrombectomies (<30
days) and only 3 patients had successful late (>30
days) thrombectomies.
Graft-related complications. In this study,
bypass graft–related complications were similar for
each type of bypass graft conduit. Graft sepsis occurred
in seven Dacron and five PTFE bypass grafts; seroma
formation that required graft replacement was seen in
two PTFE bypass grafts. Early anastomotic bypass
graft revision was necessary in three PTFE bypass
grafts and in no Dacron bypass grafts. Several nonran-
domized, nonprospective studies10-13,18-20 had sug-
gested higher rates of complications with Dacron con-
duits, but this difference may also have been explained
by different antibiotic prophylaxis and the use of
nonexternally supported bypass grafts. In the random-
ized study of aortic bypass grafts by Polteraurer et al,8
more redo operations were required in the PTFE
group. In general, graft-related complications were so
low (4.0%) that this randomized study is not large
enough to detect a difference, if one exists between
Dacron and PTFE grafts.
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